| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPT.1721 |
| P698 | PubMed publication ID | 31721171 |
| P50 | author | Juntra Karbwang | Q56804632 |
| P2093 | author name string | Kesara Na-Bangchang | |
| Marco Siccardi | |||
| Rajith K R Rajoli | |||
| Teerachat Saeheng | |||
| P2860 | cites work | Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria | Q17485067 |
| Review of Human Immunodeficiency Virus Type 1–Related Opportunistic Infections in Sub‐Saharan Africa | Q22242974 | ||
| Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine | Q24673530 | ||
| PBPK modeling and simulation in drug research and development | Q28066513 | ||
| Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study | Q28139876 | ||
| Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort | Q28477246 | ||
| Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. | Q30357429 | ||
| A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance | Q33532744 | ||
| Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration | Q33692808 | ||
| Pharmacogenetics: potential for individualized drug therapy through genetics | Q34273202 | ||
| Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. | Q34503553 | ||
| Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials | Q34822693 | ||
| Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir | Q35002453 | ||
| Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults | Q36359372 | ||
| Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. | Q37094229 | ||
| Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation | Q38075335 | ||
| PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways | Q39247285 | ||
| Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria | Q39370925 | ||
| Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir | Q39395865 | ||
| Plasma quinine concentrations in falciparum malaria with acute renal failure | Q39496894 | ||
| Disposition of oral quinine in acute falciparum malaria | Q39499380 | ||
| Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir | Q40189483 | ||
| Therapeutic drug monitoring of quinine | Q43743140 | ||
| The critical relationship between compliance and the management of infectious diseases | Q43800438 | ||
| Biowaiver monographs for immediate-release solid oral dosage forms: quinine sulfate | Q44046255 | ||
| Metabolism and elimination of quinine in healthy volunteers | Q44550877 | ||
| Mechanism-based inactivation of CYP3A by HIV protease inhibitors | Q45137041 | ||
| Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment | Q45419593 | ||
| Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. | Q46237124 | ||
| Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers | Q46453838 | ||
| Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria | Q47852106 | ||
| Quinine dosage in severe malaria with renal failure necessitating haemodialysis | Q47898028 | ||
| Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine | Q48006398 | ||
| In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. | Q48360475 | ||
| CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. | Q50572166 | ||
| Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. | Q53213264 | ||
| Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review | Q56365831 | ||
| Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro. | Q64933146 | ||
| Determination of quinine in serum, plasma, red blood cells and whole blood in healthy and Plasmodium falciparum malaria cases by high-performance liquid chromatography | Q70723005 | ||
| Pharmacokinetics of quinine in patients with chronic renal failure | Q71256039 | ||
| Antiarrhythmic Activity of Quinine in Humans | Q71807504 | ||
| Physiological parameters in laboratory animals and humans | Q72935917 | ||
| A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition | Q73546083 | ||
| Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer | Q84498183 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| lopinavir | Q422585 | ||
| ritonavir | Q422618 | ||
| P304 | page(s) | 1209-1220 | |
| P577 | publication date | 2019-11-13 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir | |
| P478 | volume | 107 |
Search more.